$43.43▴ 0.56%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
Fair value
Fairly valued
Trading right around our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Veracyte, Inc.'s earnings-quality signal is not available yet.
Key numbers
Recent news
Sentiment · last 30 days15 articles
14 bullish1 neutral0 bearish
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026
Veeva Unveils Falcon Router to Streamline Biopharma Case Routing
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now
Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx